Efficacy, safety and cost of new cardiovascular drugs: A survey

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To assess the type and degree of innovation of the cardiovascular drugs centrally approved in the European Union between 1995 and 2002. Sources of information were the European Public Assessment Reports and the Summaries of Product Characteristics published by the European Medicines Evaluation Agency. The Agency approved 11 active substances belonging to 5 therapeutic classes: anti-hypertensives, anti-arrhythmics, anti-platelets, anti-coagulants and fibrinolytics. Analysis of the documentation on which the marketing authorisation was based shows few elements of innovation. Moreover, the new drugs usually cost more than similar drugs already available. Cardiovascular drugs approved in Europe in the last few years have contributed little to progress in this area. These approvals provide no real advantage to patients and lay an economic burden on society.

Original languageEnglish
Pages (from-to)701-706
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume59
Issue number8-9
DOIs
Publication statusPublished - Nov 2003

Fingerprint

Cardiovascular Agents
Safety
Costs and Cost Analysis
Coagulants
Drug Costs
Anti-Arrhythmia Agents
European Union
Marketing
Documentation
Antihypertensive Agents
Blood Platelets
Economics
Pharmaceutical Preparations
Surveys and Questionnaires
Therapeutics

Keywords

  • Cardiovascular drugs
  • Drug regulation
  • European market

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Efficacy, safety and cost of new cardiovascular drugs : A survey. / Garattini, Silvio; Bertele', Vittorio.

In: European Journal of Clinical Pharmacology, Vol. 59, No. 8-9, 11.2003, p. 701-706.

Research output: Contribution to journalArticle

@article{1650445150374b70abad2016504e1edb,
title = "Efficacy, safety and cost of new cardiovascular drugs: A survey",
abstract = "To assess the type and degree of innovation of the cardiovascular drugs centrally approved in the European Union between 1995 and 2002. Sources of information were the European Public Assessment Reports and the Summaries of Product Characteristics published by the European Medicines Evaluation Agency. The Agency approved 11 active substances belonging to 5 therapeutic classes: anti-hypertensives, anti-arrhythmics, anti-platelets, anti-coagulants and fibrinolytics. Analysis of the documentation on which the marketing authorisation was based shows few elements of innovation. Moreover, the new drugs usually cost more than similar drugs already available. Cardiovascular drugs approved in Europe in the last few years have contributed little to progress in this area. These approvals provide no real advantage to patients and lay an economic burden on society.",
keywords = "Cardiovascular drugs, Drug regulation, European market",
author = "Silvio Garattini and Vittorio Bertele'",
year = "2003",
month = "11",
doi = "10.1007/s00228-003-0634-y",
language = "English",
volume = "59",
pages = "701--706",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "8-9",

}

TY - JOUR

T1 - Efficacy, safety and cost of new cardiovascular drugs

T2 - A survey

AU - Garattini, Silvio

AU - Bertele', Vittorio

PY - 2003/11

Y1 - 2003/11

N2 - To assess the type and degree of innovation of the cardiovascular drugs centrally approved in the European Union between 1995 and 2002. Sources of information were the European Public Assessment Reports and the Summaries of Product Characteristics published by the European Medicines Evaluation Agency. The Agency approved 11 active substances belonging to 5 therapeutic classes: anti-hypertensives, anti-arrhythmics, anti-platelets, anti-coagulants and fibrinolytics. Analysis of the documentation on which the marketing authorisation was based shows few elements of innovation. Moreover, the new drugs usually cost more than similar drugs already available. Cardiovascular drugs approved in Europe in the last few years have contributed little to progress in this area. These approvals provide no real advantage to patients and lay an economic burden on society.

AB - To assess the type and degree of innovation of the cardiovascular drugs centrally approved in the European Union between 1995 and 2002. Sources of information were the European Public Assessment Reports and the Summaries of Product Characteristics published by the European Medicines Evaluation Agency. The Agency approved 11 active substances belonging to 5 therapeutic classes: anti-hypertensives, anti-arrhythmics, anti-platelets, anti-coagulants and fibrinolytics. Analysis of the documentation on which the marketing authorisation was based shows few elements of innovation. Moreover, the new drugs usually cost more than similar drugs already available. Cardiovascular drugs approved in Europe in the last few years have contributed little to progress in this area. These approvals provide no real advantage to patients and lay an economic burden on society.

KW - Cardiovascular drugs

KW - Drug regulation

KW - European market

UR - http://www.scopus.com/inward/record.url?scp=0345598086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345598086&partnerID=8YFLogxK

U2 - 10.1007/s00228-003-0634-y

DO - 10.1007/s00228-003-0634-y

M3 - Article

C2 - 12961050

AN - SCOPUS:0345598086

VL - 59

SP - 701

EP - 706

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 8-9

ER -